Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 184Myelodysplastic Syndromes 82Leukemia 39Leukemia, Myelomonocytic, Chronic 36Recurrence 24Myeloproliferative Disorders 15Congenital Abnormalities 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Lymphoma, Large B-Cell, Diffuse 13Neoplasms 11Primary Myelofibrosis 9Melanoma 9Blast Crisis 9Thrombocythemia, Essential 7Polycythemia Vera 7Leukemia, Myelomonocytic, Acute 7Leukemia, Myelogenous, Chronic, BCR-ABL Positive 7Leukemia, Monocytic, Acute 7Hodgkin Disease 7Carcinoma, Non-Small-Cell Lung 7Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 6Ovarian Neoplasms 6Myelodysplastic-Myeloproliferative Diseases 6Anemia, Refractory, with Excess of Blasts 6Neoplasm Metastasis 5Lymphoma 5Leukemia, Myeloid, Accelerated Phase 5Leukemia, Biphenotypic, Acute 5Lymphoma, Non-Hodgkin 4Lung Neoplasms 4

Interventions

Azacitidine 5venetoclax 4Specimen Handling 3Nivolumab 2regorafenib 1midostaurin 1iadademstat 1fludarabine phosphate 1fludarabine 1decitabine and cedazuridine drug combination 1Whole-Body Irradiation 1Vorinostat 1Thiotepa 1Tacrolimus 1Methotrexate 1Lenalidomide 1Injections 1Decitabine 1Cytarabine 1Cyclophosphamide 1Busulfan 1Bone Marrow Transplantation 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × GATA2 Deficiency × Decitabine × Clear all
NCT03092674 2025-01-16

Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

National Cancer Institute (NCI)

Phase 2/3 Completed
76 enrolled 16 charts
MyeloidOther hematologic neoplasm

GATA2 Deficiency, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡